Relation between combining evidence-based medications on mortality following myocardial infarction in patients with and without renal impairment

References

• Intercontinental Marketing Service. IMS Retail Drug Monitor. Available at: http://www.ims-global.com/insight.htm (27 June 2007).
   Google Scholar
• timac D, Vukugio I, ulig J. Outpatient drug utilization in the City of Zagreb 2002-2003. Pharmaca 2004; 42: 174-89 (in Croatian).
   Google Scholar
• Bergman V. Drug utilization. Available at: “http://www.hzzo-net.hr/informacije/POTRCANJA LIJEKOVA.pdf (14 Feb-ruary 2005).
   Google Scholar
• Anonymous. Hrvatski zdravs.tveno statisti6ki ljetopis za 2005. godinu. Hrvatski zavod za javno zdravs.tvo [Croatian Health Statistics Yearbook 2005. Croatian Institute of Public Health]. Zagreb, 2006.
   Google Scholar
• Wessling A, Boethius G. Measurement of drug use in a defined population. Evaluation of the Defined Daily Dose (DDD) methodology. Eur J Gun Pharmacol 1990; 39: 207–10.
   Google Scholar
• Merlo J, Wessling A, Melander A. Comparison of dose standard units for drug utilisation studies. Eur J Gun Phar-macol 1996; 50: 27–30.
   Google Scholar
• Anatomical Therapeutic Chemical (ATC) Classification Index with Defined Daily Doses (DDDs). January 2001. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 2001.
   Google Scholar
• Anatomical Therapeutic Chemical (ATC) Classification Index with Defined Daily Doses (DDDs). January 2002. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 2002.
   Google Scholar
• Anatomical Therapeutic Chemical (ATC) Classification Index with Defined Daily Doses (DDDs). January 2003. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 2003.
   Google Scholar
• Anatomical Therapeutic Chemical (ATC) Classification Index with Defined Daily Doses (DDDs). January 2004. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 2004.
   Google Scholar
• Anatomical Therapeutic Chemical (ATC) Classification Index with Defined Daily Doses (DDDs). January 2005. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 2005.
   Google Scholar
• Bergman U, Popa C, Tomson Y, Wettermark B, Einarson TR, Aberg H, Sjoqvist F. Drug utilization 90% - a simple method for assessing the quality of drug prescribing. Eur J Clin Pharmacol 1998; 54: 113–8.
   Google Scholar
• Hrvatski zavod za javno zdravs.tvo. Medunarodna klasi-fikacija bolesti i srodnih zdravs.tvenih problema, MKB-10. Deseta revizija, Svezak 1. [Croatian Institute of Public Health. International Classification of Diseases and Related Health Problems, ICD-10. Tenth Revision]. Medicinska naklada, Zagreb, 1994.
   Google Scholar
• Vrhovac B et al., eds. Farmakoterapijski prinfónik [Hand-book in Pharmacotherapy. 5th edition]. Vizdanje. Medicin-ska naklada, Zagreb, 2007.
   Google Scholar
• Chang JT, Staffa JA, Parks M, Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil com-bination therapy. Pharmacoepidemiol Drug Saf 2004; 13: 417–26.
   Google Scholar
• Povjerenstvo za dijagnostiku i lije6enje kroni6nog zatajivanja srca Europskog kardiologkog drugtva. Smjernice za dijag-nostiku i lije6enje kroni6noga zatajivanja srca. Hrvatsko izdanje. Hrvatsko kardiologko drugtvo [Commission on the Diagnosis and Treatment of Chronic Heart Failure, Euro-pean Society of Cardiology. Guidelines on the Diagnosis and Treatment of Chronic Heart Failure. Croatian edition. Croatian Society of Cardiology], Zagreb, 2006.
   Google Scholar
• Povjerenstvo za dijagnostiku i lije6enje akutnog zatajivanja srca Europskog kardiologkog drugtva. Smjernice za dijag-nostiku i lije6enje akutnog zatajivanja srca. Hrvatsko izdanje. Hrvatsko kardiologko drugtvo [Commission on the Diag-nosis and Treatment of Acute Heart Failure, EuropeanSociety of Cardiology. Guidelines on the Diagnosis and Treatment of Chronic Heart Failure. Croatian edition. Croatian Society of Cardiology], Zagreb, 2006.
   Google Scholar
• Chatterjee K. Congestive heart failure: what should be the initial therapy and why? Am J Cardiovasc Drugs 2002; 2: 1–6.
   Google Scholar
• Deneer VH, Borgh MB, Kingma JH, Lie-A-Huen L, Brouw-ers JR. Oral antiarrhythmic drugs in converting recent onset atrial fibrillation. Pharm World Sci 2004; 26: 66–78.
   Google Scholar
• Danish Medicines Agency. Amount sold per 1000 inhabi-tants per day, Denmark in total, Primary health care sector. Available at: http://www.dkma.medstat.dk
   Google Scholar
• National Agency for Medicines, Finland. Drug consump-tion in 2003-2006. Available at: http://www.nam.fi
   Google Scholar
• Jansen R, Niemeyer MG, Cleophas TJ, Zwinderman AH. Factors influencing efficacy of nitrate therapy for stable angina pectoris: a multiple linear regression analysis. Angi-ology 2000; 51: 1007–12.
   Google Scholar
• Gogia H, Mehra A, Parikh S. Raman M, Ajit-Uppal J, John-son JV, Elkayam U. Prevention of tolerance to hemody-namic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol 1995; 26: 1575–80.
   Google Scholar
• Povjerenstvo za dijagnostiku i lije6enje hipertenzije Europ-skog kardiologkog drugtva. Europsko kardiologko drugtvo 2003. Smjernice za dijagnosticiranje i lije6enje arterijske hipertenzije. Hrvatsko izdanje. Hrvatsko kardiologko drugtvo [Commission on the Diagnosis and Treatment of Hyper-tension, European Society of Cardiology, 2003. Guidelines on the Diagnosis and Treatment of Arterial Hypertension. Croatian edition. Croatian Society of Cardiology], Zagreb, 2003.
   Google Scholar
• ALLHAT Collaborative Research Group. Major cardiovas-cular events in hypertensive patients randomized to doxa-zosin vs. chlorthalidone: the antihypertensive and lipid-low-ering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283: 1967–75.
   Google Scholar
• Scheen AJ, Krzesinski JM. Clinical study of the month. Which initial antihypertensive? Results from the ALLHAT trial. Rev Med Liege 2003; 58: 47–52.
   Google Scholar
• Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ; Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583–92.
   Google Scholar
• Fisher MA, Avorn J. Economic implications of evidence-based prescribing for hypertension. Can better care cost less? JAMA 2004; 291: 1850–6.
   Google Scholar
• Neutel JM, Smith DH, Ram CV, Lefkowitz MP, Kazem-pour MK, Weber MA. Comparison of bisoprolol with atenolol for systemic hypertension in four population groups (young, old, black and nonblack) using ambulatory blood pressure monitoring. Bisoprolol Investigators Group. Am J Cardiol 1993; 72: 41–6.
   Google Scholar
• Basile J. The role of existing and newer calcium channel blockers in the treatment of hypertension. J Clin Hypertens (Greenwich) 2004; 6: 621-9; quiz 630–1.
   Google Scholar
• Zaliunas R, Jurkevicus R, Zabiela V, Brazdzionyte J. Effect of amlodipine and lacidipine on left ventricular diastolic and long axis functions in arterial hypertension and stable angina pectoris. Acta Cardiol 2005; 60: 239–46.
   Google Scholar
• Essential Medicines. WHO Model List (revised March 2005) Explanatory Notes.14th edition (March 2005). Available at:http://www.whaint/medicines/publicationskssentialmedicines/en/
   Google Scholar
• Szucs TD, Burnier M, Erne P. Cost-effectiveness of losartan versus atenolol in treating hypertension — an analysis of the LIFE study from a Swiss perspective. Cardiovasc Drugs Ther 2004; 18: 391–7.
   Google Scholar
• Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, Hilbrich L, Pogue J, Schumacher H; ONTAR-GET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their com-bination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004; 148: 52–61.
   Google Scholar
• Maggioni AP, Fabbri G. VALIANT (VALsartan in Acute myocardial iNfarcTion) trial. Exp. Opin Pharmacother 2005; 6: 507–12.
   Google Scholar
• Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK, Warnica JW, Khrakovskaya M, Arnold JM, Schwartz Y, Velazquez EJ, Califf RM, McMurray JV, Pfeffer MA. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation 2005; 111: 3411–9.
   Google Scholar
• Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Low-ering Arm (ASCOT-LLA): a multicentre randomised con-trolled trial. Lancet 2003; 361: 1149–58.
   Google Scholar
• Wei L, Ebrahim S, Bartlett C, Davey PD, Sullivan FM, MacDonald TM. Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ 2005; 330: 821.
   Google Scholar
• Teixeira IJ, Escoval A, Schiappa M. Lipid-lowering drugs: use and expenditure in Portugal (1995-2004). Rev Port Car-diol 2007; 26: 475–93.
   Google Scholar
• Teeling M, Bennett K, Feely J. The influence of guidelines on the use of statins: analysis of prescribing trends 1998-2002. Br J Clin Pharmacol 2005; 59: 227–32.
   Google Scholar